Currently submitted to: JMIR Research Protocols
Date Submitted: Apr 17, 2026
Open Peer Review Period: Apr 21, 2026 - Jun 16, 2026
(closed for review but you can still tweet)
NOTE: This is an unreviewed Preprint
Warning: This is a unreviewed preprint (What is a preprint?). Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn (a note "no longer under consideration" will appear above).
Peer review me: Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period (in this case, a "Peer Review Me" button to sign up as reviewer is displayed above). All preprints currently open for review are listed here. Outside of the formal open peer-review period we encourage you to tweet about the preprint.
Citation: Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author).
Final version: If our system detects a final peer-reviewed "version of record" (VoR) published in any journal, a link to that VoR will appear below. Readers are then encourage to cite the VoR instead of this preprint.
Settings: If you are the author, you can login and change the preprint display settings, but the preprint URL/DOI is supposed to be stable and citable, so it should not be removed once posted.
Submit: To post your own preprint, simply submit to any JMIR journal, and choose the appropriate settings to expose your submitted version as preprint.
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
ADHD Pharmacotherapy in the Context of Coexisting Eating Disorders: A Scoping Review Protocol
ABSTRACT
Background:
Eating disorders (EDs) and attention-deficit/hyperactivity disorder (ADHD) co-occur at rates substantially exceeding chance, potentially due to shared neurodevelopmental, genetic, and reward-processing mechanisms. Despite growing clinical recognition of this overlap, no comprehensive synthesis of the effects of ADHD pharmacotherapy on ED outcomes in individuals with co-occurring ADHD and EDs currently exists. Clinicians prescribing ADHD medications to this population must balance potential risks, including appetite suppression, weight loss, and misuse, against possible benefits, including improved impulse control, improved engagement in ED treatment, and reduced binge-eating frequency, all in the absence of astructured evidence base to draw upon.
Objective:
This scoping review aims to: (1) map existing evidence on the effects of ADHD pharmacotherapy on ED symptom outcomes in individuals with co-occurring ADHD and EDs; (2) characterise the safety and tolerability profile of ADHD medications in this population; (3) describe the range of study designs, populations, medication types, and outcome measures re- ported in the literature; and (4) identify key methodological gaps to inform future research priorities.
Methods:
The review will follow the PRISMA Extension for Scoping Reviews methodology. Eligible studies will include individuals with a formal diagnosis of ADHD or clinically significant ADHD symptoms, alongside a diagnosed ED or clinically significant ED pathology, across all ED diagnoses and age groups. Any pharmacological agent approved or used off-label for ADHD, including stimulants and non-stimulants, will be eligible as the primary intervention. All study designs will be included, from randomised controlled trials to case reports, consistent with the anticipated sparsity of controlled trial data in this population. Seven electronic databases will be searched (MEDLINE, Embase, PsycINFO, PubMed, CENTRAL, Web of Science, SCOPUS), alongside trial registries and manual searches. Title/abstract and full-text screening will be conducted independently by two reviewers, with discrepancies resolved by a senior reviewer. Findings will be synthesised narratively, structured by population group, medication class, and outcome domain.
Results:
Ethics & Dissemination Ethical approval is not required as this review involves secondary analysis of publicly available data. Findings will be disseminated via peer-reviewed publication and are intended to inform prescribing practice, highlight evidence gaps, and provide a foundation for future controlled research at the intersection of ADHD and EDs.
Conclusions:
Ethics & Dissemination: Ethical approval is not required as this review involves secondary analysis of publicly available data. Findings will be disseminated via peer-reviewed publication and are intended to inform prescribing practice, highlight evidence gaps, and provide a foundation for future controlled research at the intersection of ADHD and EDs.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.